Podcast Summary: The Clay Travis and Buck Sexton Show - "The Tudor Dixon Podcast: The Hidden Effects of SSRIs on Pregnancy with Dr. Tracy Beth Hoeg"

Release Date: August 15, 2025
Host: Tudor Dixon
Guest: Dr. Tracy Beth Hoeg, Senior Advisor for Clinical Sciences at the U.S. Food and Drug Administration (FDA)

Introduction

In this compelling episode of The Clay Travis and Buck Sexton Show, hosted by Tudor Dixon, the discussion zeroes in on the intricate and often underexplored topic of Selective Serotonin Reuptake Inhibitors (SSRIs) and their effects during pregnancy. Dr. Tracy Beth Hoeg, a senior advisor at the FDA, joins Tudor to shed light on the potential impacts of these commonly prescribed antidepressants on both expectant mothers and their developing babies.

Understanding SSRIs and Their Role in Pregnancy

03:27 – 06:59
Tudor Dixon opens the dialogue by clarifying what SSRIs are, emphasizing their primary use as antidepressants. Dr. Hoeg elaborates on a pivotal panel discussion featuring Dr. Adam Jurado, a leading expert on SSRIs, who underscores the significance of serotonin in fetal brain development. She highlights that SSRIs cross the placental barrier, thereby influencing the baby's brain development[^1].

Notable Quote:
Dr. Hoeg: "Serotonin plays a critical role in fetal development. If we're altering serotonin, we would expect to find alterations in the development of the baby." [04:22]

Potential Adverse Effects on Fetal Development

07:10 – 12:23
The conversation delves into specific adverse effects associated with SSRIs. Dr. Hoeg mentions Paxil as an example, noting its FDA-listed safety signals related to heart malformations and persistent pulmonary hypertension in newborns. She also touches upon increased risks of postpartum hemorrhage in mothers. The discussion shifts to the rising concerns about increased autism rates and neurodevelopmental disorders, questioning whether these trends are influenced by SSRI usage during pregnancy.

Notable Quote:
Tudor Dixon: "We know that over 5% of women in the United States when they're pregnant are on these medications. And what impact is it having?" [07:10]

FDA’s Transparency and Public Awareness

12:23 – 17:06
Dr. Hoeg expresses her admiration for the FDA's shift towards greater transparency, especially under the guidance of Dr. Makary. She applauds the recent panel discussions that bring these critical issues to the public forefront, noting that such openness was previously absent. This transparency is vital for informing women of childbearing age about the potential risks associated with SSRIs, enabling them to make more informed decisions before conceiving.

Notable Quote:
Dr. Hoeg: "We need to be more upfront with informing the public. And to me, just the panel was a huge step that we have not seen." [08:02]

Overmedication and the Quest for Root Causes

17:06 – 28:04
The dialogue shifts to a broader critique of the overmedication trend in the United States. Dr. Hoeg and Tudor discuss how SSRIs often serve as a symptomatic mask rather than addressing the root causes of depression, such as hormonal imbalances during menopause or pregnancy. They contrast the U.S. approach with that of Denmark, where there’s a tendency to explore non-pharmaceutical interventions before resorting to medications. This segment underscores the necessity for healthcare providers to prioritize comprehensive evaluations over quick pharmaceutical fixes.

Notable Quote:
Dr. Hoeg: "We're trying to treat depression by masking it with medication rather than getting to the root cause of the problem." [25:55]

Challenges Within the Healthcare System

28:04 – 32:34
Dr. Hoeg shares her personal experiences navigating the healthcare system, particularly as a breast cancer survivor. She highlights systemic barriers that discourage patients from seeking alternative treatments, such as the rigid pathways requiring multiple appointments with different specialists to obtain a prescription. This rigidity often leads to frustration and feelings of helplessness among patients, who may not receive personalized care tailored to their unique physiological and psychological needs.

Notable Quote:
Dr. Hoeg: "There's such a massive push for medication. And I think...we are over medicated as a country." [25:55]

The Importance of Informed Decision-Making

32:09 – 35:18
As the conversation nears its conclusion, both Tudor and Dr. Hoeg emphasize the critical importance of informed decision-making in healthcare. They advocate for patients to seek out physicians with specialized training in hormone replacement therapy and to engage in open dialogues about the benefits and risks of medications like SSRIs. This segment underscores the need for societal and medical shifts towards prioritizing holistic and individualized patient care.

Notable Quote:
Tudor Dixon: "If you're experiencing symptoms of menopause, it may be a net benefit for you as an individual to take hormone replacement therapy." [16:40]

Conclusion

The episode wraps up with heartfelt reflections from both hosts. Dr. Hoeg commends the ongoing efforts to democratize medical knowledge and encourage public engagement in critical health discussions. Tudor Dixon echoes this sentiment, expressing optimism about the potential for positive change within the FDA and the broader medical community.

Final Notable Quote:
Dr. Hoeg: "You can go ask someone else. You are in the United States of America." [32:34]

Key Takeaways

1. SSRIs and Fetal Development: SSRIs cross the placental barrier, potentially affecting fetal brain development and increasing risks of heart malformations and persistent pulmonary hypertension.

2. Rising Autism Rates: There is an ongoing investigation into whether SSRI usage during pregnancy contributes to increased autism and neurodevelopmental disorder rates.

3. FDA Transparency: The FDA is making strides towards greater transparency, allowing for more open public discussions about the risks associated with medications like SSRIs.

4. Overmedication Concerns: There is a critical need to address the overreliance on medications to manage conditions like depression, advocating for treatments that target underlying causes.

5. Healthcare System Barriers: Patients often face systemic challenges when seeking personalized care, highlighting the need for more integrated and patient-centered healthcare models.

6. Informed Decision-Making: Encouraging patients to engage in open dialogues with specialized healthcare providers can lead to more informed and effective healthcare choices.

Notable Quotes with Timestamps

• Dr. Tracy Beth Hoeg:
  "Serotonin plays a critical role in fetal development. If we're altering serotonin, we would expect to find alterations in the development of the baby." [04:22]

• Tudor Dixon:
  "We know that over 5% of women in the United States when they're pregnant are on these medications. And what impact is it having?" [07:10]

• Dr. Hoeg:
  "We need to be more upfront with informing the public. And to me, just the panel was a huge step that we have not seen." [08:02]

• Dr. Hoeg:
  "We're trying to treat depression by masking it with medication rather than getting to the root cause of the problem." [25:55]

• Dr. Hoeg:
  "You can go ask someone else. You are in the United States of America." [32:34]

Final Thoughts

This episode serves as a crucial reminder of the complex interplay between medication, maternal health, and fetal development. By bringing experts like Dr. Tracy Beth Hoeg into the conversation, Tudor Dixon facilitates a nuanced exploration of SSRIs’ hidden effects during pregnancy, advocating for increased transparency, informed patient choices, and a shift towards addressing the root causes of mental health struggles rather than relying solely on pharmaceutical interventions.

[^1]: Reference to timestamps and quotes as per transcript.